AC 0058TA

Drug Profile

AC 0058TA

Alternative Names: AC 0058; AC-0058TA

Latest Information Update: 03 May 2017

Price : $50

At a glance

  • Originator ACEA Biosciences
  • Class Antirheumatics; Small molecules
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Autoimmune disorders

Most Recent Events

  • 01 Apr 2017 ACEA Biosciences completes a phase I trial in Autoimmune disorders (In volunteers) in USA (PO) (NCT02847325)
  • 01 May 2016 Phase-I clinical trials in Autoimmune disorders (In volunteers) in USA (PO) (NCT02847325)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top